You may leave me a review on these links:

Dr Jenny Nobes

  • Consultant Clinical Oncologist


Awards received

  • Eastern Clinical Research Network award for excellence in cancer research 2019
  • Macmillan Quality Improvement award for prostate brachytherapy service 2019
  • NNUH Level 2 Local Clinical Excellence Award 2016

Clinical interests

Prostate cancer:

  • HDR brachytherapy
  • Rectal spacers
  • Radiotherapy and systemic drug treatments (curative and palliative)
  • General health impact of hormone therapy

Skin cancer:

  • Melanoma immunotherapy and targeted therapy in the adjuvant and palliative settings
  • Palliative systemic therapy for non-melanoma skin cancers
  • Radiotherapy for benign and malignant skin lesions

Publications & affiliations

  • Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic.
    Rembielak A, Sykes AJ, Fife K, Challapalli A, Nobes JP.Rembielak A, et al. Clin Oncol (R Coll Radiol). 2020 Jul;32(7):417-419. doi: 10.1016/j.clon.2020.04.014.
  • Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma – Introducing the PERM Trial. Yip K, Melcher A, Harrington K, Illidge T, Nobes J, Webster A, Smith D, Lorigan P, Nathan P, Larkin J.Yip K, et al. Clin Oncol (R Coll Radiol). 2018 Apr;30(4):201-203. doi: 10.1016/j.clon.2018.01.001.
  • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators, Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan K, Coltart R, Gee B, Gore M, Farrugia D, Martin-Clavijo A, Marsden J, Price C, Farrugia D, Nathan K, Coltart R, Nathan K, Coltart R.Corrie PG, et al. Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229.
  • Metabolic syndrome and prostate cancer: a review. Nobes JP, Langley SE, Laing RW.Nobes JP, et al. Clin Oncol (R Coll Radiol). 2009 Apr;21(3):183-91. doi: 10.1016/j.clon.2008.11.013.
  • The Royal College of Radiologists’ audit of prostate brachytherapy in the year 2012. Stewart AJ, Drinkwater KJ, Laing RW, Nobes JP, Locke I.Stewart AJ, et al. Clin Oncol (R Coll Radiol). 2015 Jun;27(6):330-6. doi: 10.1016/j.clon.2015.02.005.

Professional memberships

  • Fellow of the Royal College of Radiologists
  • British Uro-Oncology Group member
  • Melanoma Focus member
  • Eastern CRN sub speciality lead for skin cancer

Dr Jenny Nobes's reviews